Loading
Latest filing published 19 Jan 2016 for Kite Pharma, Inc.. Read the official filing
No signal scores available.
Jeffrey Wiezorek appears in our data through filings on Kite Pharma, Inc. shares, published by SEC (Form 4). Activity is concentrated on a single trading day, 15 January 2016, with 7 filings.
No open-market purchase appears, only 6 sales. The amount is not disclosed for 6 filings. Other entries cover 1 option exercise.
The newest entry dates from 19 January 2016: an option exercise, in Kite Pharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations